domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -133,6 +133,12 @@ India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% pr
 
 ---
 
+### Additional Evidence (extend)
+*Source: [[2026-03-21-dr-reddys-semaglutide-87-country-export-plan]] | Added: 2026-03-21*
+
+The Delhi High Court ruling enabling Indian generic exports creates a bifurcated global market where 48% of the world's obesity burden will have access to generic semaglutide by end-2026, while US/EU/Japan markets remain under patent protection until 2031-2033. This means the 'inflationary through 2035' timeline applies primarily to Western markets, while developing markets will see deflationary pressure from generic competition starting 2026. The Canada launch (May 2026) will be the first high-income country test case for generic semaglutide pricing and utilization patterns.
+
+
 Relevant Notes:
 - [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]] -- GLP-1s are the largest single contributor to the inflationary cost trajectory
 - [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] -- VBC's promise of bending the cost curve faces GLP-1 spending as a direct counterforce

inbox/queue/.extraction-debug/2026-03-21-dr-reddys-semaglutide-87-country-export-plan.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "delhi-high-court-evergreening-rejection-enables-indian-generic-semaglutide-exports-to-patent-expired-countries.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "generic-semaglutide-reaches-48-percent-global-obesity-burden-by-end-2026-creating-parallel-market-us-patent-wall-cannot-contain.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "delhi-high-court-evergreening-rejection-enables-indian-generic-semaglutide-exports-to-patent-expired-countries.md:set_created:2026-03-21",
+      "generic-semaglutide-reaches-48-percent-global-obesity-burden-by-end-2026-creating-parallel-market-us-patent-wall-cannot-contain.md:set_created:2026-03-21"
+    ],
+    "rejections": [
+      "delhi-high-court-evergreening-rejection-enables-indian-generic-semaglutide-exports-to-patent-expired-countries.md:missing_attribution_extractor",
+      "generic-semaglutide-reaches-48-percent-global-obesity-burden-by-end-2026-creating-parallel-market-us-patent-wall-cannot-contain.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-21"
+}

inbox/queue/2026-03-21-dr-reddys-semaglutide-87-country-export-plan.md

@@ -7,9 +7,13 @@ date: 2026-03-09
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp1, semaglutide, dr-reddys, india-export, patent-court, global-generics, canada, evergreening]
+processed_by: vida
+processed_date: 2026-03-21
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -72,3 +76,11 @@ PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic catego
 WHY ARCHIVED: The court ruling is the enabling legal event for the global generic rollout. Without it, Indian manufacturers faced patent litigation risk even in countries where primary patents expired. The ruling removes that risk and establishes the "evergreening" challenge precedent.
 
 EXTRACTION HINT: The extractor should focus on: (1) the court's "evergreening and double patenting" rejection — this is a legal standard that will govern future generic challenges; (2) the 48% of global obesity burden coverage by end-2026; (3) the Canada May 2026 launch as the first high-income-country generic launch.
+
+
+## Key Facts
+- Delhi High Court division bench ruled March 9, 2026 in favor of Dr. Reddy's
+- Dr. Reddy's is India's largest generic pharmaceutical exporter
+- Semaglutide patent expiry dates: India March 20, 2026; Canada January 2026; China March 2026; Brazil 2026; Turkey 2026; US/EU/Japan 2031-2033
+- Dr. Reddy's targeting 87 countries for generic semaglutide starting 2026
+- 10 countries with 2026 patent expiries represent 48% of global obesity burden